Amended and Restated Change in Control Agreement (March 1st, 2013)
This agreement is dated December 21, 2012 and is by and between HALOZYME THERAPEUTICS, INC., a Delaware corporation (the "Company," "us," "we" or "our"), and Gregory Frost ("you" or "your").
Loan and Security Agreement (March 1st, 2013)
Separation Agreement and General Release of All Claims (March 11th, 2011)
This Separation Agreement and General Release of All Claims (Separation Agreement) is made by and between Halozyme Therapeutics, Inc. (Halozyme) and Jonathan E. Lim (Employee) as of December 2, 2010 with respect to the following facts:
Halozyme Therapeutics, Inc. 2007 Senior Executive Incentive Plan (May 9th, 2008)
The 2007 Senior Executive Incentive Plan of Halozyme Therapeutics, Inc. (the Company) set forth maximum cash and equity bonus awards for the Companys senior executive officers (the 2007 Incentive Plan). Maximum cash and equity bonus amounts were established for each executive officer (amounts for selected members of senior management are set forth in the table below) based upon the accomplishment of both individual and Company performance criteria during 2007. The maximum cash bonus amount for each executive officer represented 30% of that officers annual base salary, with the exception that the maximum cash bonus amount for the Companys Chief Executive Officer represented 40% of his base salary. The individual performance criteria for specific members of senior management varied from position to position, but all members of senior management had common Company performance goals. The Company performance criteria were based upon operational, clinical and financial performance objectives
Stock Purchase Agreement (February 20th, 2007)
This STOCK PURCHASE AGREEMENT (this Agreement), dated as of February 13, 2007, is entered into by and between Halozyme Therapeutics, Inc., a Nevada corporation (the Company), and Baxter International Inc., a Delaware company (the Purchaser), for the purchase and sale of 2,070,394 shares of the Companys Common Stock, par value $.001 per share (the Shares).
Agreement for Services (April 23rd, 2004)
This AGREEMENT FOR SERVICES is made this __ day of November, 2003 (the Effective Date) by and between Avid Bioservices, Inc., a Delaware corporation, (hereinafter referred to as AVID), having its principal office at 14282 Franklin Avenue, Tustin, CA 92780, USA and Hyalozyme Therapeutics, Inc, a California corporation, (hereinafter referred to as "COMPANY"), having its principal office at 11588 Sorrento Valley Road, Suite-17, San Diego, CA 92121, USA.